Educational pharmacology article. Revised 10 November 2026. Not a substitute for clinical protocols, local labeling or individual assessment.
Overview
Antiplatelet drugs inhibit arterial platelet activation and aggregation. They are central to acute coronary syndromes (ACS), post-PCI management and selected secondary stroke prevention, but inappropriate use increases major bleeding. Drug choice and duration are determined by ischemic versus bleeding risk and indication [1, 2, 3].
Classes and correct mechanisms
- Aspirin: irreversibly acetylates platelet cyclooxygenase-1, decreasing thromboxane A2 synthesis for the platelet lifespan.
- P2Y12 antagonists: clopidogrel and prasugrel are irreversible thienopyridine prodrugs; ticagrelor reversibly inhibits P2Y12; IV cangrelor acts rapidly and reversibly.
- GPIIb/IIIa inhibitors: eptifibatide and tirofiban inhibit final fibrinogen-mediated platelet aggregation; used selectively around PCI.
- Phosphodiesterase and adenosine-related agents: dipyridamole elevates cyclic nucleotides through PDE inhibition and adenosine reuptake effects; cilostazol mainly inhibits PDE3, not PDE5. Neither is interchangeable with standard P2Y12 inhibition [1].
ACS and PCI — 2025 guideline
The 2025 ACC/AHA ACS guideline defaults to aspirin plus a P2Y12 inhibitor for at least 12 months following ACS in patients who are not at high bleeding risk. Ticagrelor or prasugrel is generally preferred over clopidogrel in ACS patients undergoing PCI when eligible. Bleeding-risk mitigation includes PPI gastroprotection for those at GI risk and carefully selected shorter or de-escalated regimens. Patients also requiring oral anticoagulation often need a shorter period of triple therapy, followed by anticoagulation with one antiplatelet drug under specialist guidance [2].
Stroke and TIA
For certain minor noncardioembolic strokes or high-risk TIAs, short-course aspirin plus clopidogrel started promptly can reduce early recurrence, followed by single-agent therapy. Long-term dual therapy is not routine for all stroke survivors. The 2026 AHA/ASA guideline favors antiplatelet rather than thrombolysis for selected non-disabling ischemic strokes [3].
Pharmacokinetics and interactions
Clopidogrel requires CYP2C19 activation; poor-metabolizer genotypes or strong CYP2C19 inhibition can impair response. Prasugrel is contraindicated with prior stroke/TIA and demands caution in older or low-weight patients. Ticagrelor is active without prodrug activation but may cause dyspnea and bradyarrhythmias and has CYP3A interactions. Omeprazole/esomeprazole can reduce clopidogrel activation; use GI protection judiciously with interaction consideration [1, 2].
Safety and practical decisions
Bleeding is the main shared adverse effect; aspirin may cause gastrointestinal ulceration and hypersensitivity. Avoid routine aspirin for primary prevention in all adults without individual risk assessment. Coordinate stopping/restarting antiplatelet therapy before surgery or invasive procedures with the prescribing cardiology/neurology team; premature interruption after stenting may provoke thrombosis [1, 2, 3].
Assessing breathlessness during ticagrelor treatment
Ticagrelor can cause dyspnoea. Asthma or COPD alone is not a labelled absolute contraindication. New breathlessness after ACS still requires assessment for causes such as heart failure, recurrent ischaemia or pulmonary disease. If symptoms are attributed to ticagrelor and are intolerable, arrange an alternative antiplatelet plan. Unplanned interruption after coronary stenting can expose the patient to thrombosis. [4, 2]
The US ticagrelor label contraindicates use in active pathological bleeding, a history of intracranial haemorrhage or hypersensitivity to the product. Check concomitant medicines for strong CYP3A inhibitors or inducers. A history of stroke or transient ischaemic attack has different implications for prasugrel, which should be avoided in those patients. [4, 2]
References
- Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
- American College of Cardiology/American Heart Association. 2025 guideline for management of patients with acute coronary syndromes. Circulation. 2025. doi:10.1161/CIR.0000000000001309. Available from: https://professional.heart.org/en/science-news/2025-guideline-for-the-management-of-patients-with-acute-coronary-syndromes/top-things-to-know
- American Heart Association/American Stroke Association. 2026 guideline for the early management of patients with acute ischemic stroke. Stroke. 2026. Available from: https://doi.org/10.1161/STR.0000000000000513
- AstraZeneca Pharmaceuticals LP. Brilinta (ticagrelor) tablets. US prescribing information. DailyMed. 2026. View source.
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.